Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ADI-212

Other · developed by Adicet Therapeutics

Phase 1/2 Most advanced trial
ACET Developer
1 Registered trials

What is ADI-212?

ADI-212 is an investigational drug studied in Prostate Cancer Metastatic.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
Adicet Therapeutics (ACET)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07793435 Phase 1/2 Prostate Cancer Metastatic Not yet recruiting ACET

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer Metastatic

More from Adicet Therapeutics

ADI-270 Phase 1/2 Prulacabtagene Leucel Phase 1

Follow ACET, the company behind ADI-212

See ACET's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACET catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.